GEN Exclusives

More »

GEN Poll

More »
May 07, 2013

Alzheimer’s Research

Baxter International’s drug candidate Gammagard is the latest Alzheimer’s therapeutic to fail in meeting its clinical endpoints. A number of other potential therapies have suffered similar fates. With these failures in mind, how can Alzheimer’s sufferers remain optimistic that relief is in sight?

Do you foresee a major breakthrough in the treatment of Alzheimer’s disease within the next 10 years?


Related content


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Disclosing Clinical Trial Data

Do you believe that conducting performance audits for new drugs will incentivize pharma firms to become more transparent?

More »